Danaher Completes Beckman Coulter Purchase
After announcing its intent in February, Danaher has now completed its acquisition of Beckman Coulter. Danaher finalized the offer with about 88.08% of all outstanding shares having been tendered, a $6.8 billion deal. Beckman Coulter will now become part of Danaher’s Life Sciences and Diagnostics segment, joining Danaher’s AB Sciex, Leica, Radiometer, and Molecular Devices businesses. In June, the European Commission approved Danaher’s pending purchase of Beckman Coulter, clearing the last regulatory hurdle to complete the acquisition. In March, the U.S. Federal Trade Commission cleared the purchase.
Luminex Completes $34M Deal for EraGen Biosciences
Luminex Corporation has completed its $34 million all-cash purchase of EraGen Biosciences, Inc., an innovator in molecular diagnostic testing technologies for infectious disease and genetic applications. The deal will further expand Luminex’s molecular diagnostic and infectious disease portfolio. “We are excited by the opportunity to expand our capabilities and product line in the important and rapidly growing infectious disease and molecular diagnostic markets with high growth, high margin, complementary assays,” said Patrick J. Balthrop, president and CEO of Luminex. The acquisition gives Luminex access to EraGen Biosciences’s collection of molecular diagnostic assays based on an innovative and proprietary technology platform called MultiCode.
DxTerity Purchases SourceMDx’s Gene Signature Portfolio
DxTerity Diagnostics has acquired intellectual property rights to several blood-based cancer diagnostic tests from SourceMDx Inc. These tests include blood-based gene expression assays for early diagnosis of breast and lung cancer, and a blood-based test for determining survival and therapy response in melanoma patients. The company has begun the process of migrating these tests to its non-enzymatic amplification technology (NEAT) platform. “The NEAT platform is perfect for blood-based genomic testing since it enables the simultaneous, direct-from-sample measurement of up to 40 gene targets,” said Bob Terbrueggen, CEO of DxTerity Diagnostics.
Roche and Merck Collaborate on Cancer Therapy Diagnostics
Roche and Merck have teamed up in an effort to develop diagnostic assays for use with Merck’s investigational cancer therapy portfolio. The partnership will focus on various technologies, including arrays and immunohistochemical technologies. Roche will provide validated and standardized assays to Merck for use in its clinical oncology programs. Merck also will expand its use of Roche’s investigational AmpliChip p53 assay in its clinical programs. “We are very pleased to showcase our leadership position in personalized healthcare by entering into this agreement with Merck. Roche hopes that, through our joint efforts, we will be able to provide companion diagnostic tests which lead to better solutions for patients worldwide,” said Paul Brown, head of Roche Molecular Diagnostics.
Mayo Clinic and Rheonix Form Alliance to Assess Warfarin Test
The Mayo Clinic and Rheonix, Inc. have reached an agreement to partner on a project that will assess the performance of a genotyping test for warfarin sensitivity in clinical and research settings. The test, developed by Rheonix, will be available for all patients of Mayo Clinic and is the subject of ongoing research for improved anticoagulation therapy. According to Mayo, the test will help physicians better determine proper dosing of warfarin for individual patients and identify whether they may be at risk either of forming blood clots due to subtherapeutic dosing or severe bleeding due to overdosing. The test will also be offered through Mayo Clinic’s reference laboratory, Mayo Medical Laboratories, and to clients throughout the world. The firm plans to submit a 510(k) application for the test to the FDA later this year.